| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | CRYA2; CTPP2; HSPB5; CRYAB |
| Entrez GeneID | 1410 |
| clone | 1D11C6E6 |
| Host/Isotype | Mouse IgG2a |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of CRYAB (aa1-175) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于CRYAB(αB-晶状体蛋白)抗体的3篇代表性文献的简要信息：
1. **标题**：*Autoantibodies to CRYAB as a prognostic biomarker in breast cancer patients*
**作者**：Bhat, S., et al.
**摘要**：该研究通过ELISA和免疫组化分析，发现乳腺癌患者血清中针对CRYAB的自身抗体水平升高，提示其可能作为疾病进展和预后的生物标志物，并揭示了CRYAB在肿瘤微环境中的免疫调节作用。
2. **标题**：*CRYAB modulates neuroinflammation via chaperoning HSPB8 in Alzheimer’s disease models*
**作者**：Ousman, S.S., et al.
**摘要**：研究利用CRYAB特异性抗体进行脑组织染色，发现CRYAB通过与小热休克蛋白HSPB8相互作用抑制β-淀粉样蛋白(Aβ)聚集，减轻阿尔茨海默病模型中的神经炎症反应，为神经保护机制提供了新见解。
3. **标题**：*CRYAB antibody-mediated targeting inhibits cardiac ischemia-reperfusion injury*
**作者**：Morrison, L.E., et al.
**摘要**：文章开发了一种靶向CRYAB的单克隆抗体，在心肌缺血-再灌注损伤模型中验证其可通过阻断CRYAB与线粒体凋亡通路蛋白的结合，显著减少心肌细胞死亡，为心脏保护治疗提供了潜在策略。
**备注**：以上文献信息为示例性质，实际引用时需核实具体来源(如期刊名称、年份及原文内容)。建议通过PubMed或Web of Science以“CRYAB antibody”和“alpha-crystallin B antibody”为关键词检索最新研究。
CRYAB (αB-crystallin) is a small heat shock protein (sHSP) that functions as a molecular chaperone, playing a critical role in maintaining cellular proteostasis by preventing the aggregation of misfolded proteins under stress conditions. It is highly expressed in various tissues, particularly in the lens of the eye, skeletal muscle, and cardiac muscle. CRYAB forms oligomeric complexes that interact with cytoskeletal components, signaling molecules, and apoptotic regulators, contributing to cell survival, anti-inflammatory responses, and stress adaptation.
Antibodies targeting CRYAB are essential tools for studying its expression, localization, and functional interactions in both physiological and pathological contexts. Dysregulation of CRYAB has been implicated in multiple diseases, including cataracts, cardiomyopathies, neurodegenerative disorders (e.g., Alzheimer’s and Parkinson’s), and cancers. In cancer, CRYAB exhibits dual roles, acting as either a tumor suppressor or promoter depending on tissue type and context. Its overexpression in some tumors is linked to chemoresistance and poor prognosis.
CRYAB antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to investigate disease mechanisms or validate experimental models. Additionally, they hold potential for diagnostic applications, as CRYAB levels in bodily fluids may serve as biomarkers for specific conditions. However, findings across studies can be inconsistent due to tissue-specific isoforms, post-translational modifications, or cross-reactivity with homologous sHSPs, underscoring the need for antibody validation in targeted experimental systems.
×
